<- Go Home

Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

Market Cap

$3.3M

Volume

423.1K

Cash and Equivalents

$13.7M

EBITDA

-$4.8M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$10.7M

Profit Margin

30.30%

52 Week High

$24.30

52 Week Low

$0.78

Dividend

N/A

Price / Book Value

0.07

Price / Earnings

-0.10

Price / Tangible Book Value

0.08

Enterprise Value

-$10.1M

Enterprise Value / EBITDA

2.08

Operating Income

-$5.2M

Return on Equity

21.92%

Return on Assets

-9.91

Cash and Short Term Investments

$14.0M

Debt

$678.3K

Equity

$27.5M

Revenue

$35.3M

Unlevered FCF

-$2.0M

Sector

Biotechnology

Category

N/A

Company Stock Pitches